RAHIMI KOSHKAKI, HASSAN
 Distribuzione geografica
Continente #
NA - Nord America 3.528
AS - Asia 2.414
EU - Europa 1.587
SA - Sud America 321
AF - Africa 128
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 7.980
Nazione #
US - Stati Uniti d'America 3.464
SG - Singapore 883
IT - Italia 668
CN - Cina 417
HK - Hong Kong 371
VN - Vietnam 261
BR - Brasile 234
IN - India 217
DE - Germania 179
FI - Finlandia 171
SE - Svezia 168
FR - Francia 82
BD - Bangladesh 66
UA - Ucraina 62
GB - Regno Unito 56
AR - Argentina 55
RU - Federazione Russa 52
EG - Egitto 34
CA - Canada 32
IE - Irlanda 31
JP - Giappone 31
ID - Indonesia 30
MA - Marocco 24
AT - Austria 23
ZA - Sudafrica 22
IQ - Iraq 21
KR - Corea 20
MX - Messico 20
NL - Olanda 18
PH - Filippine 17
CI - Costa d'Avorio 16
PL - Polonia 15
BG - Bulgaria 14
TG - Togo 14
PK - Pakistan 11
VE - Venezuela 9
CO - Colombia 8
SA - Arabia Saudita 8
BE - Belgio 7
ES - Italia 7
TR - Turchia 7
EC - Ecuador 6
KZ - Kazakistan 6
LT - Lituania 6
RO - Romania 6
IR - Iran 5
KE - Kenya 5
OM - Oman 5
HU - Ungheria 4
KG - Kirghizistan 4
PE - Perù 4
CH - Svizzera 3
CR - Costa Rica 3
CZ - Repubblica Ceca 3
JO - Giordania 3
TH - Thailandia 3
TW - Taiwan 3
UZ - Uzbekistan 3
AL - Albania 2
BH - Bahrain 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
ET - Etiopia 2
GA - Gabon 2
GT - Guatemala 2
IL - Israele 2
JM - Giamaica 2
LK - Sri Lanka 2
MY - Malesia 2
NO - Norvegia 2
NP - Nepal 2
PA - Panama 2
PS - Palestinian Territory 2
PT - Portogallo 2
PY - Paraguay 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AO - Angola 1
AU - Australia 1
AZ - Azerbaigian 1
BO - Bolivia 1
CY - Cipro 1
DK - Danimarca 1
GE - Georgia 1
GH - Ghana 1
GR - Grecia 1
HR - Croazia 1
KN - Saint Kitts e Nevis 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MM - Myanmar 1
MN - Mongolia 1
RS - Serbia 1
SC - Seychelles 1
TJ - Tagikistan 1
TZ - Tanzania 1
UG - Uganda 1
Totale 7.979
Città #
Singapore 455
Ashburn 373
Hong Kong 364
Fairfield 353
Rome 323
San Jose 243
Chandler 170
Woodbridge 166
Seattle 144
Dallas 115
Cambridge 113
Houston 112
Wilmington 106
Beijing 103
New York 95
Los Angeles 92
Helsinki 89
Ann Arbor 81
Ho Chi Minh City 75
Santa Clara 71
Munich 67
Princeton 63
Hanoi 60
The Dalles 56
Buffalo 53
Plano 51
Hillsboro 50
Lauterbourg 46
San Paolo di Civitate 37
Boston 34
Dearborn 32
Frankfurt am Main 32
Lawrence 32
Council Bluffs 30
Dublin 30
Turku 30
Damanhur 29
Milan 28
San Diego 26
Da Nang 25
Millbury 25
Tokyo 24
Redondo Beach 23
Jakarta 22
São Paulo 21
Jacksonville 20
Falkenstein 19
Federal 19
Cosenza 18
Hefei 18
Boardman 17
Casablanca 17
Guangzhou 17
Abidjan 16
Andover 16
Nuremberg 16
Johannesburg 15
Moscow 15
Chicago 14
Lomé 14
Sofia 14
London 13
Tianjin 11
Fremont 10
Montreal 10
Norwalk 10
Toronto 10
Bremen 9
Haiphong 9
Hyderabad 9
Naples 9
Vienna 9
Baghdad 8
Indore 8
Lappeenranta 8
Palermo 8
Phoenix 8
Rio de Janeiro 8
Stockholm 8
Wroclaw 8
Bengaluru 7
Brussels 7
Dhaka 7
Falls Church 7
Mexico City 7
Orem 7
Turin 7
Atlanta 6
Latina 6
Paris 6
Putignano 6
Warsaw 6
Bari 5
Belo Horizonte 5
Biên Hòa 5
Brasília 5
Buenos Aires 5
Chennai 5
Diano d'Alba 5
Grafing 5
Totale 5.126
Nome #
TK inhibitor pazopanib primes DCs by downregulation of the β-catenin pathway 225
Bevacizumab-based chemotherapy triggers immunological effects in responding multi-treated recurrent ovarian cancer patients by favoring the recruitment of effector t cell subsets 220
Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial 213
Circulating CD137+ T cell levels are correlated with response to pembrolizumab treatment in advanced head and neck cancer patients 194
Transplantation of stem/progenitor cells isolated from human fetal biliary tree into two patients with advanced liver cirrhosis 190
Anisakis pegreffii impacts differentiation and function of human dendritic cells 189
The macrophage Galactose-type C-type Lectin (MGL) modulates regulatory T cell functions 189
MGL receptor and immunity: when the ligand can make the difference 186
The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer. A meta-analysis 171
Tumor-derived microvesicles modulate antigen cross-processing via reactive oxygen species-mediated alkalinization of phagosomal compartment in dendritic cells 165
MGL lectin receptor and immunosuppression networks in glioblastoma 162
Anticorpi monoclonali contro la lipasi da Candida rugosa 154
Transplantation of human fetal biliary tree stem/progenitor cells into two patients with advanced liver cirrhosis. 152
A comparative analysis of serum and serum-free media for generation of clinical grade DCs 152
Past, present and future strategies of immunotherapy in gynecological malignancies 149
Microvesicle cargo of tumor-associated MUC1 to dendritic cells allows cross-presentation and specific carbohydrate processing. 147
Immune effects of trastuzumab. 147
Human antibodies against the polymorphic epithelial mucin in ovarian cancer patients recognise a novel sequence in the tandem repeat region 145
IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137 + T-cells 138
Tumor derived Microvesicles enhance cross-processing ability of clinical grade Dendritic Cells 136
Preliminary results of a triple peptide escalating dose vaccination phase I/II clinical trial as consolidation treatment in women affected by ovarian cancer 134
Macrophage galactose-like lectin mediated interactions: investigating immunosuppressive mechanisms in glioblastoma 132
Production of interferon-γ by lymphocytes from paroxysmal nocturnal haemoglobinuria patients: Relationship with clinical status 128
Investigating patterns of immune interaction in ovarian cancer: probing the O-glycoproteome by the macrophage galactose-like C-type Lectin (MGL) 127
IgM-rheumatoid factor as a novel biomarker for a reduced survival in anti-PD-1 treated NSCLC patients through the decrease of CD137+T-cells 127
ANTIMICROBIAL LIPASE ANTIBODIES THEIR NUCLEOTIDE AND AMINOACID SEQUENCES AND USES THEREOF”. 126
Funzione immunoregolatoria dell'antigene tumore associato MUC1 durante l'ematopoiesi 125
Multiple Tumor Associated Peptide Vaccination As Consolidation Treatment In Women Affected by Breast and Ovarian Cancer 124
Glycan-Lectin Interactions as Novel Immunosuppression Drivers in Glioblastoma 124
Soluble PD-L1 as a prognostic factor for Immunotherapy treatment in solid tumors: systematic review and meta-analysis 122
Antimicrobial lipase antibody their nucleotide and aminoacid sequences and uses thereof 122
Human decay accelerating factor transgenic pigs for xenotransplantation obtained by sperm-mediated gene transfer 120
Immunohistochemical characterization of immune infiltrate in tumor microenvironment of glioblastoma 116
Targeting of macrophage galactose-type C-type lectin (MGL) induces DC signaling and activation 116
Enhancement of Candida rugosa lipase activity by immunoglobulin light chain 114
Immunomodulatory effects of tyrosine kinase inhibitors (TKIs) in renal cell carcinoma (RCC) patients 114
Regulated expression of MUC1 epithelial antigen in erythropoiesis 114
Immunogenic cell death and immunomodulatory effects of cabozantinib 114
Transplantation of human fetal biliary tree stem/progenitor cells into two patients with advanced liver cirrhosis 113
HER2-based recombinant immunogen to target DCs through Fc gamma Rs for cancer immunotherapy 112
Proteomic characterization of extracellular vesicles released by third stage larvae of the zoonotic parasite anisakis pegreffii (Nematoda: Anisakidae) 111
Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs 111
RFA strongly modulates the immune system and anti-tumor immune responses in metastatic liver patients 110
T cell activation induced by MUC1 synthetic glycopeptides 108
Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients 104
Generation and characterisation of monoclonal antibodies against lipases from Candida rugosa 99
Engagement of MGL by the Tn-tumor glycoform of MUC1 induces DC signaling and activation 97
Enhancement of Candida rugosa lipase activity by immunoglobulin light chain 97
Circulating CD137+ T cell levels are correlated with response to Pembrolizumab treatment in advanced head and neck cancer patients 95
Monoclonal antibodies against Candida rugosa lipase 95
hDAF TRANSGENIC PIG GENERATION: A NEW SOURCE OF ORGANS FOR XENOTRANSPLANTATION 93
Immune response to the polymorphic epithelial mucin (PEM) 91
Seasonal modulation of the C-type lectin MGL on human DCs 86
Immunoglobulin light chain increases enzymatic activity of Candida rugosa lipase. 85
Isolation of MUC-1 primed B lymphocytes from tumour draining lymph nodes using immunomagnetic beads. 85
Polymeric nanoparticles decorated with monoclonal antibodies: a new immobilization strategy for increasing lipase activity 85
MUC1 expression in non lymphoid differential cell lineages from CD34+ cells 82
Transfected human dendritic cells to induce antitumor immunity 79
Immunomodulatory effects of radiofrequency tumor ablation in liver tumor patients. 77
Dendritic cells for MUC1-based cancer immunotherapy 76
Immunoregulatory function of MUC1 tumor antigen during hematopoiesis 74
Immunomodulatory effects of radiofrequency tumor ablation in liver tumor patients 74
Immunomodulatory function of tumor antigen carrying vesiscles. 73
Modulation of blood circulating immune cells by radiofrequency tumor ablation. 67
MUC1 tumor antigen as cross talk molecule during hematopoietic differentiation 65
null 64
null 60
null 25
null 22
Totale 8.238
Categoria #
all - tutte 24.222
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 638
selected - selezionate 0
volume - volumi 0
Totale 24.860


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202113 0 0 0 0 0 0 0 0 0 0 0 13
2021/2022678 14 29 47 35 92 20 12 59 48 37 158 127
2022/2023724 138 137 40 71 72 61 11 59 58 14 31 32
2023/2024589 31 75 34 40 82 120 18 57 10 57 30 35
2024/20251.451 39 52 78 66 59 75 71 62 260 128 174 387
2025/20263.106 326 189 327 300 308 154 448 110 273 373 193 105
Totale 8.238